Diabetic; Foot UlcersNCT02331147
Allogenic Dermis Versus Standard Care in the Management of Diabetic Foot Ulcers
A study testing Offloading and Dressing Application in people with Diabetic; Foot Ulcers, run by Musculoskeletal Transplant Foundation at 3 sites in United States.
Trial summary
This is comparison trial comparing human dermis to standard wound care for non healing diabetic wound Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Diabetic; Foot Ulcers
- What is being tested?
- Offloading and Dressing Application
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 3 sitesUnited States
- Study dates
- Dec 2014to Mar 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Patients age 18 or older.
- Patient is willing to provide informed consent and is willing to participate in all procedures and follow up evaluations necessary to complete the study.
- Patient's ulcer must be diabetic in origin and larger than 1 cm2.
- Patients with Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes mellitus per ADA).
- Ulcer must be present for a minimum of four weeks before enrollment randomization, with documented failure of conventional ulcer therapy to heal the wound.
- A two week run-in period will precede enrollment/ randomization in the trial to document the indolent nature of the wounds selected.
Show all 15Show fewer
- Additional wounds may be present but not within 3 cm of the study wound.
- Wound must be present anatomically on the foot as defined by beginning below the malleoli of the ankle and be neuropathic in origin.
- Patient's ulcer must exhibit no clinical signs of infection.
- Serum Creatinine less than 3.0mg/dl within last six months.
- HbA1c less than or equal to 12% within last 90 days.
- Patient has adequate circulation to the affected extremity, as demonstrated by one of the following within the past 60 days:
- Dorsum transcutaneous oxygen test (TcPO2) with results ≥30mmHg,
- ABIs with results of ≥0.7 and ≤1.2, OR
- Doppler arterial waveforms, which are triphasic or biphasic at the ankle of affected leg.
Who cannot join
- Patients presenting with an ulcer probing to tendon, muscle, capsule or bone (UT Grade IIIA-D). A positive probe-to-bone will be confirmed when bone or joint can be felt with a sterile, ophthalmological probe.
- Patients whose index diabetic foot ulcers are greater than 25 cm2.
- Patients considered not in reasonable metabolic control, confirmed by an HbA1c greater than 12% within previous 90 days.
- Patients whose serum creatinine levels are 3.0mg/dl or greater within the last six months.
- Patients with a known history of poor compliance with medical treatments.
- Patients who have been previously randomized into this study, or are presently participating in another clinical trial.
Show all 19Show fewer
- Patients who are currently receiving radiation therapy or chemotherapy.
- Patients with known or suspected local skin malignancy to the index diabetic ulcer.
- Patients diagnosed with autoimmune connective tissues diseases.
- Non-revascularizable surgical sites.
- Active infection at site.
- Any pathology that would limit the blood supply and compromise healing.
- Patients that have received a biomedical or topical growth factor for their wound within the previous 30 days.
- Patients who are pregnant or breast feeding.
- Patients who are taking medications that are considered immune system modulators which could affect graft incorporation.
- Patients with known hypersensitivity to components of any treatment used in the trial.
- Wounds greater than one year in duration without intermittent healing.
- Wounds improving greater than 20% over the first two weeks (run-in period) of the trial using standard of care dressing and camboot.
- Patients taking Cox-2 inhibitors.
Trial locations and contacts
3 sites in 1 country.
United States3 sites
Shenandoah Lower Extremity Research
Roanoke, Virginia, 24013
Professional Education and Research Institute
Roanoke, Virginia, 24016
Foot and Ankle Associates of Southwest VA
Salem, Virginia, 24153
About this study
Official title: A Prospective, Randomized, Comparative Parallel Study of Allogenic Dermis Graft in the Management of Diabetic Foot Ulcers
This is comparison trial comparing human dermis to standard wound care for non healing diabetic wound
Read the detailed description
This is a prospective, randomized, comparative, parallel group, Multi-center clinical trial comparing the proportion of ulcers completely healed by use of allogenic dermal graft versus the standard protocol of wound care in diabetic patients with a diabetic foot ulcer with adequate arterial perfusion, for wound healing to the affected limb. The primary objective of this study is to compare the proportion of ulcers completely healed by the allogenic dermal graft protocol of care to the standard protocol of care in the management of indolent diabetic ulcers at 6 weeks. The secondary objectives of this study are to compare the proportion of healing at 4 weeks, 12 weeks and, the mean time to healing. Patient after signing IRB approve informed consent, upon meeting inclusion/exclusion criteria will be randomized into one of two group. One group receiving standard of care protocol, with an offloading boot, and one group received human allogenic dermis application, with compressive dressing and offloading boot. Patients will be seen weekly or until complete healing occurs. Measurements will be taken of the diabetic ulcers using the a centimeter ruler measuring length by width.
- Conditions
- Diabetic; Foot Ulcers
- Being tested
- Offloading, Dressing Application
- Medical subject headings
- Diabetic Foot
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OffloadingOther
Patient will be offloaded in a diabetic camboot after treatment
Dressing ApplicationOther
Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
| Study group | Role | What they receive |
|---|---|---|
| Standard of Care | Sham comparator | Surgical debridement of DFU, The wound will be debrided and cleaned. Patient ulcers will be assessed and measured weekly in cm length by width. Application of collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice off loading Receives: Other: Offloading |
| Human Dermis | Active comparator | Application of Human Allogenic Dermis with Dressing Application, to be changed weekly. Patient would will be measured in cm length by width weekly Patient will practice Offloading.
If the ulcer has not closed completely, an additional piece of Human Dermis will be applied weekly at weeks 2-11 in a similar fashion Receives: Other: Offloading; Other: Dressing Application |
What is being measured
The primary outcome is the main question the study is designed to answer.
proportion of ulcers completely healed by the allogenic dermal graft protocol of care to the standard protocol of care in the management of indolent diabetic ulcers at 6 weeks
Measured: 6 weeks
Secondary outcomes (3)
Compare the proportion of ulcers completely healed at 4 weeks
Measured: 4 weeks
Compare the proportion of ulcers completely healed at 12 weeks
Measured: 12 weeks
Mean time to healing
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jan 2015 (estimated)
- Study startDec 2014
- Primary completionMar 2017
- Study completionMar 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetic; Foot UlcersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Musculoskeletal Transplant Foundation
- Sponsor type
- University, hospital or other
- Collaborators
- Professional Education and Research Institute
- Responsible party
- Sponsor
- Investigators
- Charles M Zelen, DPM, Principal investigator, CEO; Professional Education and Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02331147
- Sponsor's protocol ID
- 20142081
- Status last verified
- Jan 2018
- First submitted
- 29 Dec 2014
- Last updated
- 1 Jun 2022
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Jun 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Randomized, Comparative Parallel Study of Allogenic Dermis Graft in the Management of Diabetic Foot Ulcers
- ClinicalTrials.gov ID
- NCT02331147
- Acronym / sponsor ID
- 20142081
- Conditions
- Diabetic; Foot Ulcers
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Musculoskeletal Transplant FoundationUniversity, hospital or other
- Collaborators
- Professional Education and Research Institute
- Study start
- Dec 2014 (actual)
- Primary completion
- Mar 2017 (actual)
- Study completion
- Mar 2017 (actual)
- First posted
- 6 Jan 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is comparison trial comparing human dermis to standard wound care for non healing diabetic wound
Detailed description
This is a prospective, randomized, comparative, parallel group, Multi-center clinical trial comparing the proportion of ulcers completely healed by use of allogenic dermal graft versus the standard protocol of wound care in diabetic patients with a diabetic foot ulcer with adequate arterial perfusion, for wound healing to the affected limb. The primary objective of this study is to compare the proportion of ulcers completely healed by the allogenic dermal graft protocol of care to the standard protocol of care in the management of indolent diabetic ulcers at 6 weeks. The secondary objectives of this study are to compare the proportion of healing at 4 weeks, 12 weeks and, the mean time to healing. Patient after signing IRB approve informed consent, upon meeting inclusion/exclusion criteria will be randomized into one of two group. One group receiving standard of care protocol, with an offloading boot, and one group received human allogenic dermis application, with compressive dressing and offloading boot. Patients will be seen weekly or until complete healing occurs. Measurements will be taken of the diabetic ulcers using the a centimeter ruler measuring length by width.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Standard of Care | Sham comparator | Other: OffloadingSurgical debridement of DFU, The wound will be debrided and cleaned. Patient ulcers will be assessed and measured weekly in cm length by width. Application of collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice off loading |
| Human Dermis | Active comparator | Other: Offloading, Other: Dressing ApplicationApplication of Human Allogenic Dermis with Dressing Application, to be changed weekly. Patient would will be measured in cm length by width weekly Patient will practice Offloading. If the ulcer has not closed completely, an additional piece of Human Dermis will be applied weekly at weeks 2-11 in a similar fashion |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (15 listed)
- Patients age 18 or older.
- Patient is willing to provide informed consent and is willing to participate in all procedures and follow up evaluations necessary to complete the study.
- Patient's ulcer must be diabetic in origin and larger than 1 cm2.
- Patients with Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes mellitus per ADA).
- Ulcer must be present for a minimum of four weeks before enrollment randomization, with documented failure of conventional ulcer therapy to heal the wound.
Key exclusion criteria (19 listed)
- Patients presenting with an ulcer probing to tendon, muscle, capsule or bone (UT Grade IIIA-D). A positive probe-to-bone will be confirmed when bone or joint can be felt with a sterile, ophthalmological probe.
- Patients whose index diabetic foot ulcers are greater than 25 cm2.
- Patients considered not in reasonable metabolic control, confirmed by an HbA1c greater than 12% within previous 90 days.
- Patients whose serum creatinine levels are 3.0mg/dl or greater within the last six months.
- Patients with a known history of poor compliance with medical treatments.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| OffloadingPatient will be offloaded in a diabetic camboot after treatment | Other | Human Dermis, Standard of Care |
| Dressing ApplicationApplication of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing. | Other | Human Dermis |
Primary outcome
proportion of ulcers completely healed by the allogenic dermal graft protocol of care to the standard protocol of care in the management of indolent diabetic ulcers at 6 weeks
Time frame: 6 weeks
3 secondary outcomes
Compare the proportion of ulcers completely healed at 4 weeks
Time frame: 4 weeks
Compare the proportion of ulcers completely healed at 12 weeks
Time frame: 12 weeks
Mean time to healing
Time frame: 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jun 2022.
Related trials for Diabetic; Foot Ulcers
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Active, not recruiting
Wearable Insoles for Recurrent Diabetic Ulcer Prevention
Diabetes, Peripheral Neuropathy
Active, not recruiting
Evaluation of Personalized Nutritional Intervention on Wound Healing of Cutaneous Ulcers in Diabetics
Foot, Diabetic
Not yet recruiting
Efficacy Evaluation of Turmeric-Derived Nanoparticle Hydrogel for the Treatment of Diabetic Foot Ulcer Wounds
Diabete Mellitus
Not yet recruiting
Better Care Closer to Home: Enhancing Primary and Community Care
Diabetic Foot Disease, Recurrence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Charles M Zelen, DPM principal investigator
CEO; Professional Education and Research Institute
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Offloading and Dressing Application in people with Diabetic; Foot Ulcers, run by Musculoskeletal Transplant Foundation at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Jun 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
proportion of ulcers completely healed by the allogenic dermal graft protocol of care to the standard protocol of care in the management of indolent diabetic ulcers at 6 weeks (time frame: 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jun 2022.